Cns Pharmaceuticals Inc

NASDAQ:CNSP  
2.04
+0.04 (+2.00%)
Products, Regulatory

CNS Pharmaceuticals Commences Patient Enrollment In Study Of Berubicin

Published: 05/19/2021 12:12 GMT
Cns Pharmaceuticals Inc (CNSP) - Cns Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin.
Cns Pharmaceuticals - Sublicensee, Wpd Pharmaceuticals to Initiate a Phase 2 Multicenter Clinical Trial in Poland of Berubicin in Gbm in H2 2021.
Cns Pharmaceuticals Inc - Interim Analysis of First 18 Adult Patients Expected in First Half of 2022.
Cns Pharmaceuticals Inc - Interim Analysis of Trial When 50% of Planned Subjects Reach 6 Months in Study.